Semaglutide yakuruye cyane kubikorwa byayo mugucunga ibiro

Nka GLP-1 agonist, yigana ingaruka za physiologique zisanzwe GLP-1 yarekuwe mumubiri.

Mu rwego rwo gufata glucose, neurone ya PPG muri sisitemu yo hagati (CNS) na L-selile zo munda itanga kandi ikarekura GLP-1, imisemburo ya gastrointestinal.

Nyuma yo kurekurwa, GLP-1 ikora reseptor ya GLP-1R kuri pancreatic β-selile, bigatera urukurikirane rwimpinduka za metabolike zirangwa no gusohora insuline no guhagarika ubushake bwo kurya.

Gusohora kwa insuline biganisha ku kugabanuka muri rusange kwa glucose mu maraso, kugabanuka kwa glucagon, no kwirinda ko glucose isohoka mu bubiko bwa glycogene y'umwijima. Ibi bitera guhaga, kunoza insuline, kandi amaherezo bikavamo kugabanuka.

Uyu muti utera insuline gusohora muburyo bwa glucose, bityo bikagabanya ibyago byo kurwara hypoglycemia. Mubyongeyeho, ifite ingaruka nziza ndende kubuzima, gukwirakwizwa, no kuvugurura β-selile.

Ubushakashatsi bwerekana ko semaglutide yigana cyane cyane ingaruka za GLP-1 zasohotse mu nda aho kuva mu bwonko. Ni ukubera ko ibyinshi mu byakira GLP-1 mu bwonko biri hanze yurwego rwiza rwibi biyobyabwenge. Nubwo ibikorwa byayo bitagaragara ku bwonko bwa GLP-1, semaglutide ikomeza kuba ingirakamaro cyane mu kugabanya ibiryo ndetse nuburemere bwumubiri.

Bigaragara ko bigerwaho mugukoresha imiyoboro ya neuronal muri sisitemu yo hagati yo hagati, inyinshi murizo ni intego ya kabiri itagaragaza neza GLP-1 yakira.

Muri 2024, verisiyo yubucuruzi yemewe ya semaglutide irimoOzempic, Rybelsus, naWegovyinshinge, zose zakozwe na Novo Nordisk.